Are you looking to connect with other families who have been impacted by PFIC? Check out the PFIC Network to connect to the global PFIC community and for resources and education! #PFICawareness #ItchingForACure #StrongerTogether
Mirum Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
Foster City, CA 35,163 followers
Creating transformative medicine for people with rare liver disease.
About us
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX). Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.
- Website
-
https://mirumpharma.com/
External link for Mirum Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Foster City, CA
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
989 E Hillsdale Blvd.
Suite 300
Foster City, CA 94404, US
Employees at Mirum Pharmaceuticals, Inc.
Updates
-
Today, October 5, marks the 6th annual Progressive Familial Intrahepatic (PFIC) Awareness Day, dedicated to sharing patient voices, spreading awareness of the disease, and coming together as a community in hopes of a better future for those living with PFIC. Join the PFIC community in planting seeds of awareness today and all month long! #PFICawareness #ItchingForACure #StrongerTogether
-
As we continue celebrating Hispanic Heritage Month, we are excited to share our team's unique cultural stories. Alejandra reflects on her Bolivian heritage and reminds us of the importance of rituals, storytelling, and the value of wisdom passed down through generations. What rituals or traditions do you carry from your heritage? #HispanicHeritageMonth #CelebratingOurStories
-
Earlier this month, our team had the privilege of attending the PBC Foundation’s 2024 Patient Conference in Edinburgh. The event was an inspiring gathering of the community to learn more about PBC and identify ways to improve the lives of those living with the disease. Thank you to the PBC Foundation for organizing an impactful event!
-
We are thrilled to celebrate Erin Osborne Murphy, Executive Director, Corporate Affairs, who was awarded the Rare Champion of Hope – Industry award by Global Genes. This well-deserved recognition reflects her passion for advocating for those living with rare disease, and this prestigious honor is a testament to her extraordinary work. Please join us in congratulating Erin on this remarkable achievement! #RAREChampion #WeekInRARE #CareAboutRare
-
We had a wonderful few days at the Global Genes' 2024 Week in Rare conference in Kansas City! This year’s theme, There’s No Place Like Hope, set a remarkable tone as we gathered together as one rare disease community to discuss the most critical issues and advance the care for rare patients. Thank you, Global Genes, for organizing an inspiring and impactful event and for offering hope for those impacted by rare diseases! #WeekInRare #TheresNoPlaceLikeHope #RareDisease
-
Though PBC month is ending, the opportunity to bring awareness to this rare disease continues! Together, the global PBC community is working together to improve the treatment and care for patients with PBC. If you haven’t already, follow the advocates who are leading the charge for a brighter future for the PBC community.
-
This month, we are honoring Hispanic Heritage Month by spotlighting the voices and perspectives of our Mirumers. Today, Alexis Isalgue shares how her Cuban heritage has influenced her life, specifically the love and respect her family has for their elders. Alexis reminds us that traditions keep the heart of a family beating strong. #HispanicHeritageMonth #CelebratingOurStories
-
We’re excited to celebrate the rich cultures and traditions of the Hispanic community. Throughout Hispanic Heritage Month, we’ll be sharing the voices and perspectives of our team members, highlighting the vibrant heritages that shape who we are at Mirum. Follow along as we spotlight the Mirumers who bring their unique experiences and cultural backgrounds to life within our organization. #HispanicHeritageMonth #CelebratingOurStories
-
Interested in elevating your medical affairs strategy? Andrea Goldstein will join other #MedicalAffairs leaders at #MASS2024, hosted by Fierce Pharma, for a dynamic panel session titled “Optimizing Medical Affairs Integration: Strategies for Building and Scaling Throughout the Development Cycle.” You won’t want to miss this on Sept 25!